,16,17 In addition, the DESTINY-Gastric01 trial evaluated T-DXd as a third- or later-line therapy in HER2+ gastric cancers in patients from Japan or the Republic of Korea compared with physician's choice of chemotherapy, demonstrating clinically meaningful and durable responses with T-DXd versus standard of care for this treatment setting.14 The gene discussed is ERBB2; the disease is gastric cancer.